Status:
WITHDRAWN
Stem Cell Therapy in Duchenne Muscular Dystrophy
Lead Sponsor:
Neurogen Brain and Spine Institute
Conditions:
Duchenne Muscular Dystrophy
Eligibility:
All Genders
3-25 years
Phase:
PHASE1
Brief Summary
The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.
Eligibility Criteria
Inclusion
- age group of 3-25 years
- Duchenne muscular dystrophy diagnosed on the basis of clinical presentation
Exclusion
- presence of respiratory distress
- presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
- malignancies
- acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction \< 30%
- pregnancy or breastfeeding
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02241434
Start Date
January 1 2009
End Date
June 1 2016
Last Update
October 25 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurogen brain and spine institute
Navi Mumbai, Maharashtra, India, 400706